The United Kingdom’s Members of Parliament voted 305 to 301 to approve an amendment to the Trade Bill that will require the nation’s negotiators to try to secure UK involvement in the European Medicines Agency (EMA) after Brexit.
This past week, the United Kingdom’s Members of Parliament voted 305 to 301 to approve an amendment to the Trade Bill that will require the nation’s negotiators to try to secure UK involvement in the European Medicines Agency (EMA) after Brexit.
News of the negotiation objective is welcome in the pharmaceutical industry, which has long warned of the need for regulatory continuity in the wake of the UK withdrawal from the European Union.
In a joint statement, Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry, and Steve Bates, chief executive of the BioIndustry Association, said, “Today, Parliament has sent a clear message that patients and public health should be a top priority for the Government in these negotiations. Every month, 37 million packs of medicine arrive in the [United Kingdom] from the [European Union] and 45 million move the other way. Therefore, it is essential that the [United Kingdom] continues to participate in the EMA after Brexit.”
Whether the European Union will be amenable to such an arrangement remains unclear, however; earlier this year, after UK Prime Minister Theresa May suggested a continued UK role in the regulatory body, the European Council signaled that, given the United Kingdom’s insistence that it will no longer remain a part of the EU single market, the European Union would not allow “cherry picking” of sectors for UK involvement.
While the UK regulatory authority, the Medicines and Healthcare Products Regulatory Agency, has sought to reassure stakeholders that it is proactively planning for all possible outcomes of Brexit negotiations concerning the EMA, concerns remain about disruption to the supply of crucial drugs after Brexit.
Earlier this month, the EMA revealed the results of a survey of UK pharmaceutical companies concerning their Brexit preparations, and while the majority of companies (94%) have plans to submit transfer applications for their products in a timely manner, the EMA issued a warning that for 108 drug products that are manufactured exclusively in the United Kingdom, there exist “serious concerns” that necessary steps to prepare for Brexit are not on track. Failure to complete crucial regulatory steps pre-Brexit could lead to supply shortages for these drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.